8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 14, 2010

STEREOTAXIS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-50884	94-3120386
(Commission File Number)	(IRS Employer Identification No.)
4320 Forest Park Avenue, Suite 100, St. Louis, Missouri	63108
(Address of Principal Executive Offices)	(Zip Code)

(314) 678-6100

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On September 14, 2010, Stereotaxis, Inc. (the “Company”) issued a press release (the “Press Release”) announcing that executive management will present at the CL King 8th Annual Best Ideas Conference to be held September 15-16, 2010 at the Omni Berkshire Place Hotel in New York City and the Stifel Nicolaus Healthcare Conference to be held September 15-17, 2010 at the Four Seasons Hotel in Boston. The Press Release is attached hereto as Exhibit 99.1.

The audio web cast of the presentation, and the investor presentation are available online on the Investor Relations portion of the Company’s website at at http://www.stereotaxis.com/Investor-Relations. The slides are attached hereto as Exhibit 99.2.

The Press Release and the presentation slides are being furnished pursuant to Item 7.01, and the information contained therein shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

The presentation slides that are attached to this Current Report on Form 8-K as Exhibit 99.2 include statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press release dated September 14, 2010.

99.2 Stereotaxis, Inc. presentation slides for conferences to be held on September 15-17

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	STEREOTAXIS, INC.
Date: September 14, 2010	By:	/s/ Daniel J. Johnston
	Name:	Daniel J. Johnston
	Title:	Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Document
99.1	Press release dated September 14, 2010.
99.2	Stereotaxis, Inc. Presentation Slides for conferences to be held on September 15-17

EX-99.1

Exhibit 99.1

Company Contact: Dan Johnston Chief Financial Officer 314-678-6007   Investor Contact: EVC Group, Inc. Douglas Sherk & Greg Gin 415-896-6820   Media Contact: EVC Group, Inc. Steve DiMattia 646-201-5445

Stereotaxis to Present at the CL King Best Ideas Conference and the Stifel Nicolaus

Healthcare Conference

St. Louis, MO, September 14, 2010 —Stereotaxis, Inc. (NASDAQ: STXS) today announced that executive management will present at the following investor conferences:

• The CL King 8^th Annual Best Ideas Conference to be held September 15-16, 2010 at the Omni Berkshire Place Hotel in New York City. Mr. Dan Johnston, Chief Financial Officer, is scheduled to review the Company’s business strategy and recent corporate developments at 2:45 PM ET on Wednesday, September 15, 2010.

• The Stifel Nicolaus Healthcare Conference to be held September 15-17, 2010 at the Four Seasons Hotel in Boston. Mr. Johnston is scheduled to review the Company’s business strategy and recent corporate developments at 10:20 AM ET on Thursday, September 16, 2010.

To listen to the audio web cast of the presentation during or after the event, or to view the investor presentation online, please visit: http://www.stereotaxis.com/Investor-Relations. The replay for the CL King presentation will be available for ninety days after the event. The replay for the Stifel Nicolaus presentation will be available for thirty days after the event.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Stereotaxis system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The unparalleled clinical capability of Stereotaxis has driven more than 130 hospitals to adopt magnetic navigation for a growing number of complex ablation cases in all four chambers of the heart. Stereotaxis technology is now installed and used by 9 out of the Top 10 Best U.S. Heart Hospitals as ranked by U.S. News and World Report, and more than one third of the EP academic training

centers in the United States have included Stereotaxis into their arrhythmia treatment laboratories. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

About Odyssey

The Odyssey portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information around the world. Odyssey Vision standardizes data integration for magnetic and standard interventional labs by enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Through its proprietary data compression technology, Cinema enables sharing of live and recorded procedure data via a laptop anywhere over a secure high speed Internet connection. Hospitals can also share procedures with other institutions using Odyssey Network Connect providing a global forum for defining clinical best practices across a broad spectrum of medical procedures.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

EX-99.2

NASDAQ: STXS

Exhibit 99.2

Forward-Looking Statements

During the course of this presentation, the Company may make projections and other forward-

looking statements regarding future events or the future financial performance of the Company,

including without limitation, statements regarding future operating results, growth opportunities

and

other

statements

that

refer

to

Stereotaxis’

plans,

prospects,

expectations,

strategies,

intentions and beliefs. These statements are subject to many risks and uncertainties that could

cause actual results to differ materially from expectations.

For a detailed discussion of risk and uncertainties that affect the Company’s business and qualify

the forward-looking statements made in this presentation, we refer you to the Company’s recent

public filings filed with the SEC, specifically the Form 10-K for the fiscal year ended December

31, 2009.

The Company’s projections and forward-looking statements are based on factors that are subject

to change and therefore these statements speak only as of the date they are given. The

Company assumes no obligation to update any projections or forward-looking statements.

In addition, regarding orders and backlog, there can be no assurance that the Company will

recognize revenue related to its purchase orders and other commitments in any particular period,

or at all, because some of these purchase orders and other commitments are subject to

contingencies that are outside of our control. These orders and commitments may be revised,

modified,

or

canceled

either

by

their

express

terms,

as

a

result

of

negotiations,

or

by

project

changes or delays.

2

Investment Considerations

Addressing market opportunity through two distinct

platforms:

Magnetic Navigation (Niobe)

Enterprise Solutions (Odyssey)

Large, high growth (+20%) cardiology ablation market

Commercial ramp began in mid 2008; leading peer

group grower in 2009 through strong fundamentals

Poised for continued growth in EP

Long term platform expansion into new markets

3

Stereotaxis

–

Magnetic Platform

Stereotaxis

steers the catheter’s distal tip through external magnetic fields thus

giving the physician precise remote control of therapeutic devices.

4

Stereotaxis

Value –

Magnetic Platform

Precise control of the distal tip of the catheter results in:

Exemplary safety

Effective lesion creation through

constant contact

Exceptional mapping capability 

Proven in all chambers of the heart

5

Before Stereotaxis

After Stereotaxis

Physician

Efficacy

Safety

Efficiency

In procedure room

Physician:

significant X-ray exposure

Patient:

major event rate ~2.8%

Wide standard deviation based on

patient and physician

In control room

Several applications clearly better than manual

-

VT, pediatrics, congenital heart diseases

Other applications comparable to manual

Almost no X-ray exposure

Major event rate reduced to 0.1%

Standardized process drives tighter distribution

around procedure times

High re-do rates

Clinical Environment Overview Market

6

Global EP Market

Source: Millennium Research Group (2009); Stereotaxis internal analysis

EP Procedures

Routine

AF

VT

Other

Total

Complex

Prevalence

Annual Procedures

Annual Growth

+20M

+10M

+3M

+5M

+18M

170k

100k

30k

40k

170k

<10%

25%

15%

15%

20%

Our

Focus

7

Strong

Clinical Validation

More than 150 Peer-Reviewed

Publications

Atrial

Fibrillation

30 Publications

Up

to

100%

acute

success

Improved

chronic

outcomes

Pediatric Arrhythmia

5 publications

93% acute success

Low fluoro, no complications

Congenital Heart

6 publications

90%

success

rate

“As easy as normal adults”

Ventricular Tachycardia

13 publications

Up

to

100%

acute

success

85%

freedom

at

1

year

Radiation Reduction

Patients

–

67%

Physicians

–

90%

1. Haghjoo,  JCE 2009.  2. Latcu, Arch Cardiovasc

Dis

2009.  3. Schwagten, PACE 2009.  4. DiBiase, JCE 2009.

5. Augello, Heart Rhythm 2009. 6. Schwagten, PACE 2009. 7. Haghjoo, JCE 2009.  8. Dibiase, Heart Rhythm 2009.

8

3

6

4

5

7

8

2

1

VT Comparison Study Erasmus MC

•

64 consecutive VT ablation patients

–

37 Stereotaxis

–

27 manual

–

Idiopathic & Scar-Related

•

No complications in Stereotaxis

group

•

1 tamponade/death in manual group

•

Conclusion: “Major

clinical & cost advantages for VT ablation”

97%

14%

170

25

8

81%

50%

228

57

13

0

50

100

150

200

250

Acute Success (%)

Recurrence (%)

Case Time (min)

Fluoro Time (min)

RF Apps

STXS

Manual

p

= 0.03

p

< 0.01

p

< 0.01

p

< 0.001

NS

9

Schwagten, et al. Eur Heart J 2010, 31(Supp):932.

Odyssey Enterprise

TM

Solutions

Odyssey Vision

10

The Odyssey Product Line

CONNECT

CINEMA

VISION

Efficiently integrate

data and control

during procedures

Standardize all labs

to increase staff

effectiveness

Drive world-class

practices by capturing,

compressing and

recording data for storage

and networking

NIOBE

Accelerate clinical

education by playing back

synchronized lab data

Drive quality of patient

care by connecting

clinical experts

Build market exposure

through live web events

showcasing clinical

capabilities

Enhance clinical

capabilities with a

robotic suite

15,000 Interventional

Standard Labs

140 Niobe

Labs

$10K / Year

$190K List

$225K -

$360K List

11

Business Model

Capital Revenue

Recurring Revenue

Niobe

Odyssey

Workstation

Odyssey

Cinema

•

141 Niobe

systems installed

•

2,500 EP labs worldwide

•

20+% growth; ~60% margin

•

25% growth (YTD 2010 vs. 2009)

•

80% margin

Equipment service

•

Technical service

•

Software license

•

1-year warranty

Niobe

Utilization

•

Stereotaxis

disposables

•

Royalty from J&J BWI

27% growth (2009 vs. 2008); 65+% margin

12

Market Adoption & Procedure Growth

Growing Worldwide Penetration

141 Systems Installed

60% US -

40% OUS

Canada -

3

United States -

77

Europe -

49

Saudi Arabia -

1

Russia -

1

China -

5

Korea -

1

Japan -

1

Singapore -

1

Taiwan -

1

Australia -

1

13

$0.0

$4.0

$8.0

$12.0

$16.0

Q1

Q2

Q3

Q4

2008

2009

2010

$11.2

$8.8

$7.2

$7.3

$5.0

$10.2

$12.4

$6.3

$11.2

$7.7

New Orders to Backlog

Revenue Momentum

Recurring Revenue

$ millions

$ millions

$0

$2

$4

$6

$8

$10

$12

$14

$16

Q1

Q2

Q3

Q4

2008

2009

2010

$7.0

$11.1

$10.6

$10.7

$12.6

$15.0

$10.6

$13.3

$12.1

$14.1

$ millions

Stereotaxis

Financial Update

14

$0.0

$4.0

$8.0

$12.0

Q1

Q2

Q3

Q4

2008

2009

2010

Total Inventory

-$20.0

-$15.0

-$10.0

-$5.0

$0.0

$5.0

Q1

Q2

Q3

Q4

Cash Flow (Burn)

$0.0

$5.0

$10.0

$15.0

$20.0

$25.0

Q1

Q2

Q3

Q4

2008

2009

2010

Operating Expenses

55.0%

60.0%

65.0%

70.0%

75.0%

Q1

Q2

Q3

Q4

2008

2009

2010

Gross Margin Percentage

$ millions

$ millions

$ millions

65.5%

68.9%

72.5%

60.8%

63.1%

65.5%

67.8%

67.6%

67.3%

$17.8

$14.8

$14.0

$18.7

$14.6

$16.1

$13.3

$14.6

$15.3

-$12.6

-$11.4

-$6.4

-$7.6

-$5.8

-$3.5

-$4.5

-$2.9

$10.5

$8.1

$4.9

$9.6

$7.5

$8.4

$7.0

$8.1

$4.4

67.2%

$15.8

$4.3

Stereotaxis

Financial Update

15

-$7.9

-$5.6

2008

2009

2010

Liquidity

$3.0

$1.3

$3.6

$0

$2

$4

$6

$8

$10

2010

Operating Cash Flow Ex A/R

BWI Debt

Accounts Receivable

Q2 2010 Cash Burn Analysis

$ Millions

$7.9

$ Millions

$26.3

$19.4

* Cash burn includes repayment of Biosense

Webster advance.

*

16

$6.6

$12.8

$4.3

$30.3

$23.8

$20.7

$22.0

$0

$5

$10

$15

$20

$25

$30

$35

Cash Burn

Cash

Credit Line Availabilty

2008

2009

TTM June

30, 2010

June 30,

2010

June 30,

2009

2010 Focus

I.

Drive Commercial Success

Clinical training/process accelerates adoption

Adoption

creates

stronger

reference

sites

Reference

sites

accelerate

capital

pipeline

&

sales

Niobe

orders generate Odyssey opportunities

Odyssey

(robotic

labs)

placements

generate

standard

lab interest

II.Strengthen EP Product Offering

Product

extensions

Odyssey

link,

Interface,

Carto

III

New

capabilities

launched

with

VDrive™

* Year to Date 2010

17

Metrics

25% growth recurring revenue*

5

17

Q2 2010 orders doubled over 2009

Odyssey revenue up 164%*

Standard lab sales 36% of total

Odyssey*

Q & A

18